Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • ESMO China Voice | Professor Sheng Xinan Reports RENOTORCH Study, Sharing the First “Domestic Innovation” Immune Combination Therapy for First-Line

    The combination of immune checkpoint inhibitors and anti-angiogenic therapy has become a first-line treatment option for advanced renal cell carcinoma (aRCC), with previous studies including patients of all IMDC risk levels. During a dedicated session on urological oncology at the 2023 ESMO Congress, Professor Sheng Xinan from Peking University Cancer Hospital, on behalf of a…

    2023.11.27
  • ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

    Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought about a breakthrough in the survival of these late-stage patients. However, some recurrent metastatic patients may develop endocrine resistance, reducing the efficacy of treatment. The European Society…

    2023.11.27
  • IDWeek Commentary | Dr. Yonghong Xiao: Intestinal colonization with MDRO, horizontal transmission and risk for bloodstream infection

    Editor’s Note: Bacterial drug resistance is a significant challenge in the global public health field. Multidrug-resistant organisms (MDROs), represented by carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa…

    2023.11.27
  • IDWeek Live interview: Clinical Trials in Fungal Diseases That May Change Your Practice

    Editor’s Note: In a special session titled “Clinical Trials That May Change Your Practice” at the 2023 Infectious Diseases Week (IDWeek 2023), Dr. George R. Thompson III of University of…

    2023.11.27
  • IDWeek Live Interview | Dr. Murat Akova: When to Discontinue Antibiotics in Febrile Neutropenia?

    Editor’s Note: The normal immune function of the body is crucial in defending against invading pathogens and maintaining the stability of the internal environment. In recent years, our understanding of…

    2023.11.27
  • IDWeek Live Interview | Dr. Patty Wright Summarizes Hot Topics in the Field of Infectious Diseases

    Editor’s Note: The IDWeek 2023 took place in Boston from October 11 to 15. On the first day during the “What’s Hot in ID + HIV” session, Dr. Patty W.…

    2023.11.27
  • IDWeek Live Interview: Dr. Kevin Downes on Practical and Novel Approaches to Therapeutic Drug Monitoring and Antibiotic Dose Optimization

    Therapeutic Drug Monitoring (TDM) refers to the practice of tailoring individualized drug dosing regimens for patients by quantitatively assessing drug exposure, pharmacokinetic markers, or pharmacodynamic endpoints based on therapeutic drug…

    2023.11.27
  • IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

    Half of all global child deaths under the age of 5 are caused by infections, and half of all sepsis patients worldwide are children, especially newborns. These alarming statistics highlight the significant challenge of infection treatment in pediatric clinical practice. At the recent IDWeek 2023 congress in the United States, a predictive model for severe…

    2023.11.27
«previous next»
Recent Posts
  • Prof. Wang Liang: How to Precisely Choose Between Autologous and Allogeneic Transplantation for First-Line Consolidation in Peripheral T-Cell Lymphoma? | 2026 Cross-Strait Hematology Conference
  • Professor Huang He: Advances in Novel Cellular Immunotherapy and Clinical Translation丨2026 Cross-Strait Hematology Academic Conference
  • CACA GU丨Yiping Zhu: Advancing Standardized, Whole-Course Bladder Cancer Management—from First-Line Treatment Innovation to Multidisciplinary Collaboration
  • 2026 Pujiang Urological Oncology Academic Conference丨Yijun Shen: ADCs Are Driving Bladder-Preservation Strategies Toward Precision Combination Therapy—from Combination Treatment in High-Risk NMIBC and MIBC Pathway Reshaping to Molecular Biomarker Stratification
  • 2026 Pujiang Urological Oncology Academic Conference丨Professor Guohai Shi: From Combination Therapy to Whole-Course Management, Advancing Long-Term Benefit in Advanced Renal Cell Carcinoma
Recent Comments
    Archives
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top